Cantor Fitzgerald raised the price target for the Verve Therapeutics Inc. (NASDAQ:VERV) stock to “a Neutral”. The rating was released on February 01, 2023, according to finviz. The research report from Credit Suisse has initiated the stock to Neutral, with a price target set at $48. The stock was upgraded by Stifel, who disclosed in a research note on August 25, 2022, from Hold to Buy and set the price objective to $56. In their research brief published June 17, 2022, BMO Capital Markets analysts initiated the Verve Therapeutics Inc. stock to Outperform with a price target of $48.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Verve Therapeutics Inc. (NASDAQ:VERV) dipped -0.76% to close Thursday’s market session at $16.92, lower as compared to yesterday’s close. The stock price fluctuated between $16.70 and $17.21 throughout the trading session with the volume trading being 836444 shares, which represented a significant variation when compared to the three months average volume of 742.78K shares. The firm’s stock price fluctuated -2.70% within the last five trades and -22.24% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -58.07% in the last 6 months and -24.63% was subtracted to its value over the previous 3 months. VERV stock is trading at a margin of -10.68%, -17.95% and -33.25% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
As of the close of trading, VERV deals in the Healthcare domain. The stock is trading -60.65 percent below its 52-week high and 58.13 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -57.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Verve Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $1.07 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 560.68 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.89, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Bellinger Andrew, the CSO & CMO at Verve Therapeutics Inc. (VERV) has sold 865 shares of firm on Dec 01 at a price of $22.95 against the total amount of $19852.0. In another inside trade, Dorval Allison, Chief Financial Officer of Verve Therapeutics Inc. (NASDAQ:VERV) sold 554 shares of the firm on Nov 29 for a total worth of $12243.0 at a price of $22.10. An inside trade which took place on Nov 04, Member of 10% Group of Verve Therapeutics Inc. GV 2017 GP, L.L.C. sold 97,166 shares of firm against total price of $3.03 million at the cost of $31.14 per share.